

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CANbridge Pharmaceuticals Inc.
北海康成製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1228)

CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

The board of directors (the “**Board**”) of CANbridge Pharmaceuticals Inc. (the “**Company**”) hereby announces that the principal place of business of the Company in Hong Kong will be changed to Room B01, 20/F, CITIC Tower, 1 Tim Mei Avenue, Admiralty, Hong Kong with effect from April 15, 2024. The website of the Company remain unchanged.

By Order of the Board
CANbridge Pharmaceuticals Inc.
Dr. James Qun Xue
Chairman

Hong Kong, April 12, 2024

As of the date of this announcement, the Board comprises Dr. James Qun Xue as executive director; Dr. Kan Chen and Mr. Edward Hu as non-executive directors; and Mr. James Arthur Geraghty, Dr. Richard James Gregory, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive directors.